Allspring Global Investments
PRLD icon

Allspring Global Investments’s Prelude Therapeutics PRLD Stock Holding History

Allspring Global Investments’s Portfolio PRLD Stock Details PRLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-6,107
Closed -$18.9K – 2629
2023
Q3 		$18.9K Buy
+6,107
New +$22.9K ﹤0.01% 2521

Other funds holding PRLD

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Allspring Global Investments's PRLD Position: Q4 2023 in Review

Allspring Global Investments sold out of Prelude Therapeutics (PRLD) in Q4 2023, closing a stake of 6,107 shares — an estimated $18.9K sold.

Allspring Global Investments first reported a position in PRLD in Q3 2023 and held it in 1 quarter. The position peaked at $18.9K in Q3 2023. 56 funds tracked by Wall St. Rank hold PRLD as of Q4 2023.

  • Allspring Global Investments reported no remaining Prelude Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Allspring Global Investments sold 6,107 Prelude Therapeutics shares in Q4 2023, an estimated $18.9K.
  • Allspring Global Investments first reported a position in Prelude Therapeutics in Q3 2023 and held it in 1 quarter.
  • Allspring Global Investments's Prelude Therapeutics position peaked at $18.9K in Q3 2023.
  • 56 funds tracked by Wall St. Rank held Prelude Therapeutics as of Q4 2023.

Based on Allspring Global Investments's 13F filing for Q4 2023, filed 25 Jan 2024.